RT Journal Article
SR Electronic
T1 Effect of Systemic Inflammatory Response to SARS-CoV-2 on Lopinavir and Hydroxychloroquine Plasma Concentrations
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.07.05.20146878
DO 10.1101/2020.07.05.20146878
A1 Marzolini, Catia
A1 Stader, Felix
A1 Stoeckle, Marcel
A1 Franzeck, Fabian
A1 Egli, Adrian
A1 Bassetti, Stefano
A1 Hollinger, Alexa
A1 Osthoff, Michael
A1 Weisser, Maja
A1 Gebhard, Caroline E.
A1 Baettig, Veronika
A1 Geenen, Julia
A1 Khanna, Nina
A1 Tschudin-Sutter, Sarah
A1 Mueller, Daniel
A1 Hirsch, Hans H.
A1 Battegay, Manuel
A1 Sendi, Parham
YR 2020
UL http://medrxiv.org/content/early/2020/07/07/2020.07.05.20146878.abstract
AB Background Coronavirus disease 2019 (COVID-19) leads to inflammatory cytokine release, which can downregulate the expression of metabolizing enzymes. This cascade affects drug concentrations in the plasma. We investigated the association between lopinavir (LPV) and hydroxychloroquine (HCQ) plasma concentrations and the values of acute phase inflammation marker C-reactive protein (CRP).Methods LPV plasma concentrations were prospectively collected in 92 patients hospitalized at our institution. Lopinavir/ritonavir was administered 12-hourly, 800/200 mg on day 1, and 400/100 mg on day 2 until day 5 or 7. HCQ was given at 800 mg, followed by 400 mg after 6, 24 and 48 hours. Hematological, liver, kidney, and inflammation laboratory values were analyzed on the day of drug level determination.Results The median age of study participants was 59 (range 24–85) years, and 71% were male. The median duration from symptom onset to hospitalization and treatment initiation was 7 days (IQR 4–10) and 8 days (IQR 5–10), respectively. The median LPV trough concentration on day 3 of treatment was 26.5 μg/mL (IQR 18.9–31.5). LPV plasma concentrations positively correlated with CRP values (r=0.37, p<0.001), and were significantly lower when tocilizumab was preadministrated. No correlation was found between HCQ concentrations and CRP values.Conclusions High LPV plasma concentrations were observed in COVID-19 patients. The ratio of calculated unbound drug fraction to published SARS-CoV-2 EC50 values indicated insufficient LPV concentrations in the lung. CRP values significantly correlated with LPV but not HCQ plasma concentrations, implying inhibition of cytochrome P450 3A4 (CYP3A4) metabolism by inflammation.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04351503Funding StatementCM was supported by the Adolf and Mary Mil Foundation FS and CEG supported by a grant from the Swiss National FoundationAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Northwest/central Switzerland Ethics Committee (EKNZ 2020-00769)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData referred to in the manuscript are available